<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30217" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Tissue Plasminogen Activator</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jilani</surname>
            <given-names>Talha N.</given-names>
          </name>
          <aff>HCA Healthcare Sunrise Health Graduate Medical Education Program</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Siddiqui</surname>
            <given-names>Abdul H.</given-names>
          </name>
          <aff>Northwell Health SIUH</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Talha Jilani declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdul Siddiqui declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>20</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30217.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Tissue plasminogen activator (tPA) is classified as a serine protease (enzymes that cleave peptide bonds in proteins). It is thus one of the essential components of the dissolution of blood clots. Its primary function includes catalyzing the conversion of plasminogen to plasmin, the primary enzyme involved in dissolving blood clots. Examples of these drugs include alteplase, reteplase, and tenecteplase. Indications for the use of tPA include ischemic stroke (most common) in patients presenting to treating facility within 3 hours (4.5 hours in certain, eligible patients) after the onset of symptoms, myocardial Infarction if there would be a delay of more than 1 to 2 hours before percutaneous transluminal coronary angioplasty, pulmonary embolism in massive pulmonary embolisms, causing severe instability due to high pressure on the heart, and thrombolysis (e.g., deep vein thrombosis). This activity outlines the indications, mechanism of action, methods of administration, significant adverse effects, contraindications, toxicity, and monitoring of tPA agents so providers can direct patient therapy where they are indicated as part of the interprofessional team.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Assess&#x000a0;the mechanism of action of tissue plasminogen activators.</p></list-item><list-item><p>Identify the indications for initiating therapy with a tPA agent, differentiating between individual agents where appropriate.</p></list-item><list-item><p>Evaluate&#x000a0;the contraindications of tPA medications.</p></list-item><list-item><p>Communicate&#x000a0;interprofessional team strategies for improving care coordination to properly use tPA agents to improve patient outcomes in varied scenarios where they can be effective.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30217&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30217">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30217.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Tissue plasminogen activator (tPA) is classified as a serine protease (an enzyme that cleaves peptide bonds in proteins). It is thus&#x000a0;1 of the essential components of blood clot dissolution. Its primary function includes catalyzing the conversion of plasminogen to plasmin, the primary enzyme involved in dissolving blood clots. Recombinant biotechnology has allowed tPA to be manufactured in labs, and these synthetic products are called recombinant tissue plasminogen activators (tPA). These drugs have undergone various modifications to amplify their pharmacokinetics and pharmacodynamics, especially prolonging their short half-life in circulation and increasing their fibrin specificity to prevent an unwanted fibrinolytic state. Examples of these drugs include alteplase, reteplase, and tenecteplase.&#x000a0;Indications for the use of tPA include&#x000a0;the following:</p>
        <list list-type="order">
          <list-item>
            <p>Ischemic stroke (most common) in patients presenting to the treating facility within 3 hours (4.5 hours in certain, eligible people) after the onset of symptoms.<xref ref-type="bibr" rid="article-30217.r1">[1]</xref><xref ref-type="bibr" rid="article-30217.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Myocardial infarction would be a delay of more than 1 to 2 hours before percutaneous transluminal coronary angioplasty.<xref ref-type="bibr" rid="article-30217.r3">[3]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Pulmonary embolism in massive pulmonary embolisms causes severe instability due to high pressure on the heart.<xref ref-type="bibr" rid="article-30217.r4">[4]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Thrombolysis (eg, deep vein thrombosis).<xref ref-type="bibr" rid="article-30217.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Definitions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Alteplase </bold>is<bold>&#x000a0;</bold>the normal human plasminogen activator and is FDA-approved for managing patients with ischemic stroke, myocardial infarction with ST-elevation, acute massive pulmonary embolism, and those with central venous access devices.<xref ref-type="bibr" rid="article-30217.r6">[6]</xref><xref ref-type="bibr" rid="article-30217.r7">[7]</xref>&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Reteplase&#x000a0;</bold>is a modified form of human tPA with similar effects but a faster onset and longer duration of action. It is currently&#x000a0;FDA-approved for the management of acute myocardial infarction. It is preferred over alteplase due to its longer half-life, allowing it to be given as a bolus injection rather than through an infusion like alteplase.<xref ref-type="bibr" rid="article-30217.r8">[8]</xref><xref ref-type="bibr" rid="article-30217.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Tenecteplase </bold>is another modified version of tPA with a longer half-life. Its indication is the management of acute myocardial infarction.<xref ref-type="bibr" rid="article-30217.r10">[10]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30217.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>tPA is a thrombolytic (ie, it breaks up blood clots) formed by aggregating activated platelets into fibrin meshes by activating plasminogen. More specifically, it cleaves the zymogen plasminogen at its Arg561-Val562 peptide bond to form&#x000a0;plasmin, a serine protease. Plasmin, an endogenous&#x000a0;fibrinolytic enzyme, breaks the cross-links between fibrin molecules, which are the structural support of the blood clot, and its activity is extremely&#x000a0;short-lived. This short duration is because alpha 2-antiplasmin, an abundant inhibitor of plasmin, quickly inactivates it and restricts the action of plasmin to the vicinity of the clot.<xref ref-type="bibr" rid="article-30217.r11">[11]</xref>&#x000a0;The following sequence summarizes the action of tPA:</p>
        <list list-type="order">
          <list-item>
            <p>tPA attaches to the fibrin on the clot surface.</p>
          </list-item>
          <list-item>
            <p>It activates the fibrin-bound plasminogen.</p>
          </list-item>
          <list-item>
            <p>Plasmin is subsequently cleaved from the plasminogen affiliated with the fibrin.</p>
          </list-item>
          <list-item>
            <p>The plasmin breaks up the molecules of fibrin, and the clot dissolves.</p>
          </list-item>
        </list>
        <p>Plasminogen activator inhibitor 1 (PAI 1) eventually terminates the catalytic activity of tPA by binding to it, and this inactive complex (PAI 1-bound tPA) is removed from the circulation by the liver via the scavenger receptor, LDL receptor-related protein 1&#x000a0;(LRRP1). In the nervous system, a neuronal-specific inhibitor of tPA, neuroserpin, acts similarly to PAI 1, and the LRRP1 internalizes the inactive tPA-neuroserpin complexes&#x000a0;for removal from circulation.<xref ref-type="bibr" rid="article-30217.r12">[12]</xref><xref ref-type="bibr" rid="article-30217.r13">[13]</xref></p>
      </sec>
      <sec id="article-30217.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Alteplase</bold>
</p>
        <p>Alteplase administration is via the intravenous route. However, for catheter clearance, it is administered directly into the catheter.</p>
        <p>
<bold>Acute Myocardial Infarction</bold>
</p>
        <p>To manage acute myocardial infarction in adults, administer alteplase as soon as possible after the onset of symptoms. The patient's weight determines the dose to be administered, which does not exceed 100 mg irrespective&#x000a0;of the selected administration method (accelerated infusion&#x000a0;preferred by the AHA/ACCA or slower, 3-hour infusion as per manufacturer's labeling).&#x000a0;</p>
        <p>Accelerated infusion (1&#x000a0;to 1/2 hr):</p>
        <list list-type="bullet">
          <list-item>
            <p>For patients who weigh less than or equal to 67 kg: 15 mg IVP bolus is administered over 1 to 2 minutes, followed by 0.75 mg/kg&#x000a0;intravenous infusion given over 30 minutes (not to exceed 50 mg), followed by 0.5 mg/kg&#x000a0;intravenously over the following 60 minutes (not to exceed 35 mg over 1 hour).</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For patients who weigh greater than 67 kg: (A total of 100 mg is infused over 1.5 hours) 15 mg intravenous pyelogram (IVP) bolus is administered over 1 to 2 minutes, followed by 50 mg&#x000a0;intravenous infusion during the next 30 minutes, and then the remaining 35 mg over the following 60 minutes.&#x000a0;</p>
          </list-item>
        </list>
        <p>&#x000a0;3-hour infusion:</p>
        <list list-type="bullet">
          <list-item>
            <p>For patients who weigh less than 65 kg: A dose of 0.075 mg/kg IVP bolus is administered over 1 to 2 minutes, followed by a 0.675 mg/kg infusion over the rest of the first hour, and, lastly, 0.25 mg/kg&#x000a0;intravenously over the next 2 hours.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients weighing 65 kg or more: A 100 mg total dose is infused over 3 hours. Six to 10 mg IVP bolus is given over 1 to 2 minutes, followed by 50 to 54 mg over the rest of the first hour (ie, 60 mg in the first hour including 6 to 10 mg bolus), and then 20 mg/hr over the next 2 hours.</p>
          </list-item>
        </list>
        <p>
<bold>Pulmonary Embolism</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Infuse 100 mg&#x000a0;intravenously over 2 hours. Institute parenteral anticoagulation towards the end of or immediately following the alteplase infusion when the thrombin time or PTT returns to less than&#x000a0;2 times&#x000a0;the reference range.</p>
          </list-item>
        </list>
        <p>
<bold>Acute Ischemic Stroke</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>A dose of 0.9 mg/kg is given through&#x000a0;intravenous infusion, not to exceed 90 mg total dose. Ten percent of the total dose is administered as an&#x000a0;intravenous bolus over 1 minute, and the remaining is gradually infused over 60 minutes.<xref ref-type="bibr" rid="article-30217.r14">[14]</xref></p>
          </list-item>
        </list>
        <p>&#x000a0; Dosing considerations for acute ischemic stroke:</p>
        <list list-type="order">
          <list-item>
            <p>Intracranial hemorrhage should be excluded as the primary cause of stroke before initiation of treatment.</p>
          </list-item>
          <list-item>
            <p>Administer alteplase as soon as possible but ideally within 3 hours after onset of symptoms.</p>
          </list-item>
          <list-item>
            <p>Monitor and control the blood pressure during and after administration.</p>
          </list-item>
          <list-item>
            <p>In patients who have not recently used oral anticoagulants or heparin, treatment can start before the coagulation study test results are available.</p>
          </list-item>
          <list-item>
            <p>Discontinue if the pretreatment INR exceeds 1.7 or the aPTT is elevated.</p>
          </list-item>
        </list>
        <p>
<bold>Arterial Thrombosis and Embolism</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>0.05&#x000a0;to 0.1 mg/kg/hr is given by transcatheter intra-arterial infusion for about 1 to 8 hours or until the lysis of the thrombus.</p>
          </list-item>
        </list>
        <p><bold>Central Venous Catheter Occlusion</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>1 mg/mL, intracatheter</p>
          </list-item>
          <list-item>
            <p>Adult patients&#x000a0;who weigh less than 30 kg: Administer 110% of the lumen volume of the catheter (intracatheter), not exceeding 2 mg/2 mL; then retain in the catheter for around 0.5 to 2 hours; can instill a second dose if the catheter remains occluded.</p>
          </list-item>
          <list-item>
            <p>Patients who weigh more than or equal to 30 kg: Administer 2 mg/2 mL, which should be retained in the catheter for around 0.5 to 2 hours. If the catheter remains occluded, a second dose can be instilled.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Pediatric patients who weigh less than 30 kg: Administer 110% of the measured internal lumen volume of the catheter with alteplase, not exceeding 2 mg/2 mL.</p>
          </list-item>
          <list-item>
            <p>Pediatric patients who weigh 30 kg or more: Instill 2 mg of alteplase into the occluded catheter.</p>
          </list-item>
        </list>
        <p>After 30 minutes of dwell time, assess the catheter's function by attempting to aspirate blood; if blood cannot be aspirated 120 minutes after dwell time, a second dose may be administered, and the process repeated. If catheter function is restored, aspirate 4 to 5 mL of blood in patients who weigh 10 kg or more (aspirate around 3 mL if the patient weighs less than 10 kg) to remove the drug and the residual clot. Then, gently irrigate with 0.9% NaCl.&#x000a0;</p>
        <p>
<bold>Pleural Catheter or Chest Tube Drainage</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Concurrent TPA and human deoxyribonuclease (DNAse) can be administered intrapleurally through the chest tube or pleural catheters. It has been shown to assist with better drainage of thick, loculated effusions like empyema.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Reteplase</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Reteplase is administered intravenously as soon as possible after the onset of symptoms.<xref ref-type="bibr" rid="article-30217.r15">[15]</xref></p>
          </list-item>
          <list-item>
            <p>Adult patients: Initially, administer 10 units of&#x000a0;intravenous bolus (over 2 minutes), with the second dose given 30 minutes after the first (for a total cumulative dose of 20 units). An&#x000a0;intravenous line is used to administer the bolus injection, and no other medication should be simultaneously injected or infused through this&#x000a0;intravenous line.</p>
          </list-item>
          <list-item>
            <p>Pediatric patient safety and efficacy are not established.</p>
          </list-item>
        </list>
        <p>
<bold>Tenecteplase</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Tenecteplase is administered intravenously&#x000a0;as soon as possible after the onset of symptoms.<xref ref-type="bibr" rid="article-30217.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p>In adult patients, administer a 30 to 50 mg&#x000a0;intravenous bolus over 5 seconds&#x000a0;1 time (based on weight): 30 mg for patients weighing less than 60 kg; 35 mg for patients weighing 60&#x000a0;to 70 kg; 40 mg for patients weighing 70-80 kg; 45 mg for patients weighing 80&#x000a0;to 90 kg; 50 mg for patients weighing more than 90 kg.</p>
          </list-item>
          <list-item>
            <p>Pediatric patient safety and efficacy not established.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30217.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Alteplase:&#x000a0;Adverse effects occur in 1% to 10% of the people who receive alteplase. The most common adverse effect is bleeding, and the most serious is a stroke. Other side effects include bruising, pulmonary edema, arterial embolism, deep vein thrombosis, orolingual angioedema, intracranial hemorrhage, shock, hypersensitivity, nausea/vomiting, seizure, ischemic stroke, thromboembolism, and sepsis.<xref ref-type="bibr" rid="article-30217.r17">[17]</xref><xref ref-type="bibr" rid="article-30217.r18">[18]</xref></p>
        <p>Tenecteplase:&#x000a0;Adverse effects occur in more than 10% of patients receiving tenecteplase. The most common is minor bleeding. Other adverse effects include fever, myocardial infarction, reperfusion arrhythmias, nausea/vomiting, edema, allergic reaction, and cholesterol embolization.<xref ref-type="bibr" rid="article-30217.r17">[17]</xref><xref ref-type="bibr" rid="article-30217.r18">[18]</xref><xref ref-type="bibr" rid="article-30217.r19">[19]</xref></p>
        <p>Reteplase:&#x000a0;As with other tPAs, the most common adverse effect seen with reteplase is bleeding. Other observed adverse effects include reperfusion arrhythmias, hypotension, nausea/vomiting, cardiogenic shock, muscle pain, allergic reaction, a reaction at the injection site, anemia, gastrointestinal/urogenital bleeding, intracranial hemorrhage, and cholesterol embolization.<xref ref-type="bibr" rid="article-30217.r18">[18]</xref><xref ref-type="bibr" rid="article-30217.r20">[20]</xref></p>
      </sec>
      <sec id="article-30217.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Do not administer tPA for the treatment of acute ischemic stroke in the following scenarios:</p>
        <list list-type="bullet">
          <list-item>
            <p>If the risk of bleeding and serious complications are greater than the potential benefit of tPA therapy. These include patients with current intracranial hemorrhage, subarachnoid hemorrhage, and those who have active internal bleeding.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>If the patient underwent recent (less than&#x000a0;3 months ago) intracranial or intraspinal surgery or suffered a serious head trauma&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Evidence of intracranial conditions that may increase the risk of bleeding</p>
          </list-item>
          <list-item>
            <p>Bleeding diathesis (hemorrhagic diathesis)</p>
          </list-item>
          <list-item>
            <p>Patients with severe uncontrolled hypertension<xref ref-type="bibr" rid="article-30217.r21">[21]</xref><xref ref-type="bibr" rid="article-30217.r22">[22]</xref><xref ref-type="bibr" rid="article-30217.r23">[23]</xref></p>
          </list-item>
        </list>
        <p>Do not administer tPA in the management of acute myocardial infarction or pulmonary embolism in&#x000a0;the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>If the risk of bleeding is greater than any potential benefit. This risk includes active internal bleeding or patients with a recent history of stroke.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Recent (within&#x000a0;3 months) intracranial or intraspinal surgery or serious head trauma</p>
          </list-item>
          <list-item>
            <p>Presence of intracranial pathologies that may increase the risk of bleeding</p>
          </list-item>
          <list-item>
            <p>Bleeding diathesis (hemorrhagic diathesis)</p>
          </list-item>
          <list-item>
            <p>Current severe uncontrolled hypertension<xref ref-type="bibr" rid="article-30217.r21">[21]</xref></p>
          </list-item>
        </list>
        <p>Do not administer tPA in any patient who had a hypersensitivity reaction to a previous dose of tPA (urticarial or anaphylactic reactions)<xref ref-type="bibr" rid="article-30217.r21">[21]</xref><xref ref-type="bibr" rid="article-30217.r24">[24]</xref></p>
      </sec>
      <sec id="article-30217.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>
<bold>Monitoring During Therapy With tPA</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Perform a regular neurologic assessment on the patient.</p>
          </list-item>
          <list-item>
            <p>Check thoroughly for major or minor bleeding.</p>
          </list-item>
          <list-item>
            <p>Continuously monitor the blood pressure of the patient.</p>
          </list-item>
          <list-item>
            <p>Check&#x000a0;for the signs and symptoms of intracranial hemorrhage.</p>
          </list-item>
          <list-item>
            <p>Check for the signs of orolingual angioedema.</p>
          </list-item>
          <list-item>
            <p>Discontinue tPA infusion and order an emergency&#x000a0;computed tomography&#x000a0;scan if the patient develops a severe headache, severe hypertension, nausea/vomiting, or a worsening neurologic examination.</p>
          </list-item>
          <list-item>
            <p>If a hypersensitivity reaction occurs in the patient, stop the tPA administration and immediately initiate supportive therapy with antihistamines and corticosteroids.<xref ref-type="bibr" rid="article-30217.r25">[25]</xref><xref ref-type="bibr" rid="article-30217.r26">[26]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Monitoring After Therapy With tPA</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Follow the patient to monitor for any neurologic deterioration.</p>
          </list-item>
          <list-item>
            <p>Check for any major or minor bleeding.</p>
          </list-item>
          <list-item>
            <p>Monitor and strictly control blood pressure.</p>
          </list-item>
          <list-item>
            <p>Order a follow-up&#x000a0;computed tomography&#x000a0;scan or MRI at least 24 hours before initiating anticoagulants or antiplatelet agents.</p>
          </list-item>
          <list-item>
            <p>Continue to monitor for hypersensitivity and signs of orolingual angioedema.<xref ref-type="bibr" rid="article-30217.r25">[25]</xref><xref ref-type="bibr" rid="article-30217.r26">[26]</xref><xref ref-type="bibr" rid="article-30217.r27">[27]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30217.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Aminocaproic acid is the drug used to reverse tPA toxicity,&#x000a0;an FDA-approved drug for managing acute bleeding caused by increased fibrinolytic activity. It acts as an effective inhibitor for proteolytic enzymes like plasmin, the primary enzyme responsible for fibrinolysis.<xref ref-type="bibr" rid="article-30217.r28">[28]</xref><xref ref-type="bibr" rid="article-30217.r29">[29]</xref></p>
        <p>
<bold>Drug Interactions</bold>
</p>
        <p>Monitor closely with any drug that causes anticoagulation as there is an increased risk of bleeding.</p>
        <list list-type="bullet">
          <list-item>
            <p>Defibrotide: Through pharmacodynamic synergism, defibrotide increases the effects of tPA drugs and is thus contraindicated.</p>
          </list-item>
          <list-item>
            <p>Prothrombin complex concentrate, human: This can cause pharmacodynamic antagonism of the tPA drugs.</p>
          </list-item>
          <list-item>
            <p>Apixaban: Apixaban and tPA drugs increase anticoagulation and can lead to an increased bleeding risk.</p>
          </list-item>
          <list-item>
            <p>Nitroglycerin: This could decrease the serum concentration of tPA drugs.</p>
          </list-item>
          <list-item>
            <p>Salicylates: These could enhance the toxic effects of thrombolytic drugs. Monitor therapy, as there is an increased risk of bleeding.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30217.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>tPA has a significant risk of causing complications as well as helping the patient. An interprofessional medical team consisting of&#x000a0;clinicians (MDs, DOs, NPs, and PAs), specialists,&#x000a0;nurses, pharmacists, and clinicians exercising open lines&#x000a0;of communication should monitor patients receiving this drug to provide the safest&#x000a0;care and best patient outcome. Interprofessional collaboration and open communication can improve patient outcomes with fewer adverse effects.</p>
      </sec>
      <sec id="article-30217.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30217&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30217">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30217/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30217">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30217.s11">
        <title>References</title>
        <ref id="article-30217.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gravanis</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tsirka</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Tissue-type plasminogen activator as a therapeutic target in stroke.</article-title>
            <source>Expert Opin Ther Targets</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>159</fpage>
            <page-range>159-70</page-range>
            <pub-id pub-id-type="pmid">18208365</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30217.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heiferman</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Pecoraro</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Smolenski</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Tsimpas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ashley</surname>
                <given-names>WW</given-names>
              </name>
            </person-group>
            <article-title>Intra-Arterial Alteplase Thrombolysis during Mechanical Thrombectomy for Acute Ischemic Stroke.</article-title>
            <source>J Stroke Cerebrovasc Dis</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>26</volume>
            <issue>12</issue>
            <fpage>3004</fpage>
            <page-range>3004-3008</page-range>
            <pub-id pub-id-type="pmid">28843804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30217.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rogers</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Riemersma</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Clements</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Tissue plasminogen activator: an evaluation of clinical efficacy in acute myocardial infarction.</article-title>
            <source>Pharmacotherapy</source>
            <year>1987</year>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>111</fpage>
            <page-range>111-21</page-range>
            <pub-id pub-id-type="pmid">3120160</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30217.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Niedermeyer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Meissner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fabel</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>[Thrombolytic therapy in pulmonary embolism. Indications and therapeutic strategies].</article-title>
            <source>Z Gesamte Inn Med</source>
            <year>1993</year>
            <season>Jun-Jul</season>
            <volume>48</volume>
            <issue>6-7</issue>
            <fpage>332</fpage>
            <page-range>332-43</page-range>
            <pub-id pub-id-type="pmid">8333230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30217.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharifi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bay</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nowroozi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bentz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Valeros</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Memari</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Catheter-directed thrombolysis with argatroban and tPA for massive iliac and femoropopliteal vein thrombosis.</article-title>
            <source>Cardiovasc Intervent Radiol</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>36</volume>
            <issue>6</issue>
            <fpage>1586</fpage>
            <page-range>1586-1590</page-range>
            <pub-id pub-id-type="pmid">23377239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30217.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Demaerschalk</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Kleindorfer</surname>
                <given-names>DO</given-names>
              </name>
              <name>
                <surname>Adeoye</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Demchuk</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Fugate</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Grotta</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Khalessi</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>EI</given-names>
              </name>
              <name>
                <surname>Palesch</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Prabhakaran</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Saposnik</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Saver</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>EE</given-names>
              </name>
              <collab>American Heart Association Stroke Council and Council on Epidemiology and Prevention</collab>
            </person-group>
            <article-title>Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.</article-title>
            <source>Stroke</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>47</volume>
            <issue>2</issue>
            <fpage>581</fpage>
            <page-range>581-641</page-range>
            <pub-id pub-id-type="pmid">26696642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30217.r7">
          <label>7</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Reed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kerndt</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Nicolas</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <chapter-title>Alteplase</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">29763152</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30217.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Qiao</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic effect evaluation of reteplase on acute pulmonary embolism.</article-title>
            <source>Pak J Pharm Sci</source>
            <year>2018</year>
            <month>May</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>899</fpage>
            <page-range>899-905</page-range>
            <pub-id pub-id-type="pmid">29716871</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30217.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>SX</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>ZN</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>XX</given-names>
              </name>
              <name>
                <surname>Lyu</surname>
                <given-names>ZC</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Hua</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jing</surname>
                <given-names>ZC</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>XQ</given-names>
              </name>
            </person-group>
            <article-title>[Clinical efficacy and safety of thrombolytic treatment with reteplase in patients with intermediate-risk acute pulmonary embolism].</article-title>
            <source>Zhonghua Xin Xue Guan Bing Za Zhi</source>
            <year>2017</year>
            <month>Apr</month>
            <day>24</day>
            <volume>45</volume>
            <issue>4</issue>
            <fpage>314</fpage>
            <page-range>314-317</page-range>
            <pub-id pub-id-type="pmid">28545283</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30217.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saran</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Sethi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nagori</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>"Tenecteplase--the best among the equals.".</article-title>
            <source>Indian Heart J</source>
            <year>2009</year>
            <season>Sep-Oct</season>
            <volume>61</volume>
            <issue>5</issue>
            <fpage>454</fpage>
            <page-range>454-8</page-range>
            <pub-id pub-id-type="pmid">20635761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30217.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Collen</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Molecular mechanism of action of newer thrombolytic agents.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>1987</year>
            <month>Nov</month>
            <volume>10</volume>
            <issue>5 Suppl B</issue>
            <fpage>11B</fpage>
            <page-range>11B-15B</page-range>
            <pub-id pub-id-type="pmid">3117858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30217.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bannish</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Chernysh</surname>
                <given-names>IN</given-names>
              </name>
              <name>
                <surname>Keener</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Fogelson</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Weisel</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Molecular and Physical Mechanisms of Fibrinolysis and Thrombolysis from Mathematical Modeling and Experiments.</article-title>
            <source>Sci Rep</source>
            <year>2017</year>
            <month>Aug</month>
            <day>07</day>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>6914</fpage>
            <pub-id pub-id-type="pmid">28785035</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30217.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kramer</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Jenne</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Holodinsky</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Todd</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Kubes</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zygun</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Leger</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and Pharmacodynamics of Tissue Plasminogen Activator Administered Through an External Ventricular Drain.</article-title>
            <source>Neurocrit Care</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>386</fpage>
            <page-range>386-93</page-range>
            <pub-id pub-id-type="pmid">25739904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30217.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheng</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>TY</given-names>
              </name>
            </person-group>
            <article-title>Impact of estimated-weight-base dose of alteplase in acute stroke treatment on clinical outcome.</article-title>
            <source>J Clin Neurosci</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>85</volume>
            <fpage>101</fpage>
            <page-range>101-105</page-range>
            <pub-id pub-id-type="pmid">33581779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30217.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yenari</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Beaulieu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Kunis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Albers</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Moseley</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>GK</given-names>
              </name>
            </person-group>
            <article-title>Thrombolysis with reteplase, an unglycosylated plasminogen activator variant, in experimental embolic stroke.</article-title>
            <source>J Stroke Cerebrovasc Dis</source>
            <year>1998</year>
            <season>May-Jun</season>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>179</fpage>
            <page-range>179-86</page-range>
            <pub-id pub-id-type="pmid">17895078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30217.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burgos</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Saver</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Evidence that Tenecteplase Is Noninferior to Alteplase for Acute Ischemic Stroke: Meta-Analysis of 5 Randomized Trials.</article-title>
            <source>Stroke</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>50</volume>
            <issue>8</issue>
            <fpage>2156</fpage>
            <page-range>2156-2162</page-range>
            <pub-id pub-id-type="pmid">31318627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30217.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Logallo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Novotny</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Assmus</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kvistad</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Alteheld</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>R&#x000f8;nning</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Thommessen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Amthor</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Ihle-Hansen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kurz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tobro</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stankiewicz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carlsson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morsund</surname>
                <given-names>&#x000c5;</given-names>
              </name>
              <name>
                <surname>Idicula</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Aamodt</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Lund</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>N&#x000e6;ss</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Waje-Andreassen</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Thomassen</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial.</article-title>
            <source>Lancet Neurol</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>16</volume>
            <issue>10</issue>
            <fpage>781</fpage>
            <page-range>781-788</page-range>
            <pub-id pub-id-type="pmid">28780236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30217.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenberg</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Steiner</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>And why not thrombolysis in the ambulance (at least for some)?</article-title>
            <source>Neurology</source>
            <year>2016</year>
            <month>Jul</month>
            <day>12</day>
            <volume>87</volume>
            <issue>2</issue>
            <fpage>214</fpage>
            <page-range>214-9</page-range>
            <pub-id pub-id-type="pmid">27306629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30217.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gomaraschi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ossoli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vitali</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pozzi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vitali Serdoz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pitzorno</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sinagra</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Franceschini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Calabresi</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Off-target effects of thrombolytic drugs: apolipoprotein A-I proteolysis by alteplase and tenecteplase.</article-title>
            <source>Biochem Pharmacol</source>
            <year>2013</year>
            <month>Feb</month>
            <day>15</day>
            <volume>85</volume>
            <issue>4</issue>
            <fpage>525</fpage>
            <page-range>525-30</page-range>
            <pub-id pub-id-type="pmid">23219857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30217.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baldo</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Enzymes approved for human therapy: indications, mechanisms and adverse effects.</article-title>
            <source>BioDrugs</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-55</page-range>
            <pub-id pub-id-type="pmid">25648140</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30217.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Changing contraindications for t-PA in acute stroke: review of 20 years since NINDS.</article-title>
            <source>Curr Cardiol Rep</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>17</volume>
            <issue>10</issue>
            <fpage>81</fpage>
            <pub-id pub-id-type="pmid">26277361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30217.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kulairi</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Deol</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tolly</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Manocha</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Naseer</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Is Intravenous Heparin a Contraindication for TPA in Ischemic Stroke?</article-title>
            <source>Case Rep Neurol Med</source>
            <year>2017</year>
            <volume>2017</volume>
            <fpage>9280961</fpage>
            <pub-id pub-id-type="pmid">28261510</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30217.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salazar</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Useche</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Granja</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morillo</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Berm&#x000fa;dez</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Ruling Out Brain CT Contraindications prior to Intravenous Thrombolysis: Diagnostic Equivalence between a Primary Interpretation Workstation and a Mobile Tablet Computer.</article-title>
            <source>Int J Telemed Appl</source>
            <year>2017</year>
            <volume>2017</volume>
            <fpage>6869145</fpage>
            <pub-id pub-id-type="pmid">29250111</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30217.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Madden</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chebl</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Hemi orolingual angioedema after tPA administration for acute ischemic stroke.</article-title>
            <source>West J Emerg Med</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>175</fpage>
            <page-range>175-7</page-range>
            <pub-id pub-id-type="pmid">25671036</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30217.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheng</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>XJ</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>GY</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>KX</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Bai</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.</article-title>
            <source>J Stroke Cerebrovasc Dis</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>381</fpage>
            <page-range>381-390</page-range>
            <pub-id pub-id-type="pmid">29111341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30217.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Atsumi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hasegawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tsumura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ueda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sugiyama</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nozaki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nakane</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nagashima</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kitamura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nikaido</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sasanuma</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Quality assurance monitoring of a citywide transportation protocol improves clinical indicators of intravenous tissue plasminogen activator therapy: a community-based, longitudinal study.</article-title>
            <source>J Stroke Cerebrovasc Dis</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>183</fpage>
            <page-range>183-8</page-range>
            <pub-id pub-id-type="pmid">25440326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30217.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alexandrov</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Demchuk</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Felberg</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Christou</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Barber</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Burgin</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Malkoff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wojner</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Grotta</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>High rate of complete recanalization and dramatic clinical recovery during tPA infusion when continuously monitored with 2-MHz transcranial doppler monitoring.</article-title>
            <source>Stroke</source>
            <year>2000</year>
            <month>Mar</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>610</fpage>
            <page-range>610-4</page-range>
            <pub-id pub-id-type="pmid">10700493</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30217.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Golembiewski</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Antifibrinolytic Use in the Perioperative Setting: Aminocaproic Acid and Tranexamic Acid.</article-title>
            <source>J Perianesth Nurs</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>30</volume>
            <issue>6</issue>
            <fpage>560</fpage>
            <page-range>560-563</page-range>
            <pub-id pub-id-type="pmid">26596393</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30217.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blaine</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Press</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sliwa</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Comparative effectiveness of epsilon-aminocaproic acid and tranexamic acid on postoperative bleeding following cardiac surgery during a national medication shortage.</article-title>
            <source>J Clin Anesth</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>35</volume>
            <fpage>516</fpage>
            <page-range>516-523</page-range>
            <pub-id pub-id-type="pmid">27871586</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
